US5900476A
(en)
*
|
1986-05-30 |
1999-05-04 |
The Scripps Research Institute |
Therapeutic domains of van Willebrand factor
|
US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
FR2719593B1
(fr)
*
|
1994-05-06 |
1996-05-31 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
JP2003530838A
(ja)
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
HUP0303251A2
(hu)
|
2001-02-27 |
2003-12-29 |
Maxygen Aps |
Béta-interferon-szerű molekulák
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
EP2316487B1
(en)
|
2003-04-11 |
2014-06-11 |
MedImmune, LLC |
Recombinant IL-9 antibodies & uses thereof
|
AU2004259727A1
(en)
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of cancer and infectious diseases.
|
AU2004282984B2
(en)
|
2003-11-13 |
2011-07-14 |
Hanmi Science Co., Ltd. |
Protein complex using immunoglobulin fragment andmethod for the preparation thereof
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
US7700720B2
(en)
|
2004-09-21 |
2010-04-20 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
PL1853718T3
(pl)
|
2005-02-15 |
2016-01-29 |
Univ Duke |
Przeciwciała anty-CD19 i zastosowania w onkologii
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
JP5047947B2
(ja)
|
2005-05-05 |
2012-10-10 |
デューク ユニバーシティ |
自己免疫疾患のための抗cd19抗体治療
|
SI2573114T1
(sl)
|
2005-08-10 |
2016-08-31 |
Macrogenics, Inc. |
Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo
|
KR20140077946A
(ko)
|
2005-10-13 |
2014-06-24 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
|
WO2007061896A1
(en)
|
2005-11-17 |
2007-05-31 |
Zogenix, Inc. |
Delivery of viscous formulations by needle-free injection
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US8268347B1
(en)
|
2006-10-24 |
2012-09-18 |
Aradigm Corporation |
Dual action, inhaled formulations providing both an immediate and sustained release profile
|
WO2008137915A2
(en)
|
2007-05-07 |
2008-11-13 |
Medimmune, Llc |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
EP2068927B1
(en)
|
2007-05-14 |
2015-10-21 |
MedImmune, LLC |
Methods of reducing eosinophil levels
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
UA117446C2
(uk)
|
2007-08-29 |
2018-08-10 |
Санофі-Авентіс |
Гуманізоване антитіло до cxcr5
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
EP2225275A4
(en)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
EP2245064B1
(en)
|
2007-12-21 |
2014-07-23 |
Medimmune Limited |
BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha)
|
JP2011518881A
(ja)
|
2008-04-28 |
2011-06-30 |
ゾゲニクス インコーポレーティッド |
片頭痛の治療のための製剤
|
EP3173424A1
(en)
|
2008-05-02 |
2017-05-31 |
Novartis Ag |
Improved fibronectin-based binding molecules and uses thereof
|
MY159396A
(en)
|
2008-08-05 |
2016-12-30 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
JP5611210B2
(ja)
|
2008-09-07 |
2014-10-22 |
グリコネックス インコーポレイテッド |
抗拡張i型スフィンゴ糖脂質抗体、その誘導体および使用
|
EP2358392B1
(en)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antibody formulation
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
WO2010123290A2
(ko)
|
2009-04-22 |
2010-10-28 |
(주)알테오젠 |
체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법
|
US11512326B2
(en)
|
2009-05-26 |
2022-11-29 |
University Of Florida Research Foundation, Incorporated |
Small angiotensin peptide expression system in mammalian cells
|
EP3381937A3
(en)
|
2009-08-13 |
2018-10-31 |
The Johns Hopkins University |
Methods of modulating immune function
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
AU2010303415B2
(en)
|
2009-10-07 |
2015-02-19 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
JP5657698B2
(ja)
|
2010-01-19 |
2015-01-21 |
ハンミ サイエンス カンパニー リミテッドHanmi Scienceco.,Ltd. |
持続型顆粒球コロニー刺激因子結合体の液剤
|
WO2011092233A1
(en)
|
2010-01-29 |
2011-08-04 |
Novartis Ag |
Yeast mating to produce high-affinity combinations of fibronectin-based binders
|
AU2011249782B2
(en)
|
2010-05-06 |
2014-10-02 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
|
BR112012028306A2
(pt)
|
2010-05-06 |
2020-11-03 |
Novartis Ag |
anticorpos para proteína 6 relacionada com lipoproteína de baixa densidade (lrp6) e seus fragmentos, seu uso, ácidos nucléicos, vetores, bem como composições farmacêuticas e combinações
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
PT2606070T
(pt)
|
2010-08-20 |
2017-03-31 |
Novartis Ag |
Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
|
AU2011293127B2
(en)
|
2010-08-27 |
2016-05-12 |
Abbvie Stemcentrx Llc |
Notum protein modulators and methods of use
|
AU2011295715B9
(en)
|
2010-09-03 |
2017-02-23 |
Abbvie Stemcentrx Llc |
Novel modulators and methods of use
|
EP2635607B1
(en)
|
2010-11-05 |
2019-09-04 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
BR112013014119A8
(pt)
|
2010-12-08 |
2017-07-11 |
Stem Centrx Inc |
Novos moduladores e métodos de uso
|
US20120171195A1
(en)
|
2011-01-03 |
2012-07-05 |
Ravindranath Mepur H |
Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
AR085911A1
(es)
|
2011-03-16 |
2013-11-06 |
Sanofi Sa |
Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
US9382305B2
(en)
|
2011-07-01 |
2016-07-05 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
JP2014529293A
(ja)
|
2011-07-08 |
2014-11-06 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH |
レラキシンを放出する融合タンパク質およびその使用
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
AU2012332587B2
(en)
|
2011-11-01 |
2017-02-23 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
US9220774B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Methods of treating cancer by administering anti-GPR49 antibodies
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
ES2697674T3
(es)
|
2011-11-01 |
2019-01-25 |
Bionomics Inc |
Procedimientos para bloquear el crecimiento de células madre cancerosas
|
ES2666856T3
(es)
|
2011-11-04 |
2018-05-08 |
Novartis Ag |
Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
|
JP6326371B2
(ja)
|
2011-11-04 |
2018-05-16 |
ザイムワークス,インコーポレイテッド |
Fcドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
|
AU2012349736A1
(en)
|
2011-12-05 |
2014-06-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain II of HER3
|
BR112014013412A8
(pt)
|
2011-12-05 |
2021-06-08 |
Novartis Ag |
anticorpos para o receptor 3 do fator de crescimento epidérmico (her3), e seus usos
|
CA2859493A1
(en)
|
2011-12-21 |
2013-06-27 |
Novartis Ag |
Compositions and methods for antibodies targeting factor p
|
US10800847B2
(en)
|
2012-01-11 |
2020-10-13 |
Dr. Mepur Ravindranath |
Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
EP3093294A1
(en)
|
2012-02-24 |
2016-11-16 |
Stemcentrx, Inc. |
Dll3 modulators and methods of use
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
US10064951B2
(en)
|
2012-03-30 |
2018-09-04 |
Hanmi Science Co., Ltd. |
Liquid formulation of highly concentrated long-acting human growth hormone conjugate
|
ES2843054T3
(es)
|
2012-05-10 |
2021-07-15 |
Zymeworks Inc |
Construcciones heteromultiméricas de cadenas pesadas de inmunoglobulina con mutaciones en el dominio Fc
|
US10656156B2
(en)
|
2012-07-05 |
2020-05-19 |
Mepur Ravindranath |
Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
|
AR091902A1
(es)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
CA2893767C
(en)
|
2012-12-05 |
2022-11-08 |
Novartis Ag |
Compositions and methods for antibodies targeting epo
|
US10981961B2
(en)
|
2013-03-11 |
2021-04-20 |
University Of Florida Research Foundation, Incorporated |
Delivery of card protein as therapy for occular inflammation
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
EP3473272A1
(en)
|
2013-03-29 |
2019-04-24 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
CN105848671B
(zh)
|
2013-08-28 |
2019-12-13 |
艾伯维施特姆森特克斯有限责任公司 |
位点特异性抗体缀合方法和组合物
|
JP2016538318A
(ja)
|
2013-08-28 |
2016-12-08 |
ステムセントリックス, インコーポレイテッド |
新規sez6モジュレーターおよび使用方法
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
WO2015153916A1
(en)
|
2014-04-04 |
2015-10-08 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
US9988443B2
(en)
|
2014-08-07 |
2018-06-05 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
NZ728425A
(en)
|
2014-08-07 |
2022-05-27 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
EP3298140B1
(en)
|
2015-05-19 |
2024-04-24 |
Yale University |
Compositions for treating pathological calcification conditions, and methods using same
|
CA2982237A1
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
RU2752530C2
(ru)
|
2015-08-03 |
2021-07-29 |
Новартис Аг |
Способы лечения расстройств, связанных с fgf21
|
CN108350070B
(zh)
|
2015-09-09 |
2022-01-28 |
诺华股份有限公司 |
胸腺基质淋巴细胞生成素(tslp)-结合分子及该分子的使用方法
|
TN2018000076A1
(en)
|
2015-09-09 |
2019-07-08 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
WO2017103895A1
(en)
|
2015-12-18 |
2017-06-22 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
WO2017122130A1
(en)
|
2016-01-11 |
2017-07-20 |
Novartis Ag |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
WO2017161414A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
US11312766B2
(en)
|
2016-04-27 |
2022-04-26 |
Novartis Ag |
Antibodies against growth differentiation factor 15 and uses thereof
|
EP3458085B1
(en)
*
|
2016-05-20 |
2022-12-07 |
Octapharma AG |
Glycosylated vwf fusion proteins with improved pharmacokinetics
|
US11434269B2
(en)
|
2016-06-15 |
2022-09-06 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
US11168147B2
(en)
|
2016-12-23 |
2021-11-09 |
Novartis Ag |
Factor XI antibodies and methods of use
|
AU2017383537A1
(en)
|
2016-12-23 |
2019-06-27 |
Novartis Ag |
Methods of treatment with anti-factor XI/XIa antibodies
|
KR102572663B1
(ko)
|
2017-02-08 |
2023-09-01 |
노파르티스 아게 |
Fgf21 모방 항체 및 이의 용도
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
KR20210016390A
(ko)
|
2018-06-01 |
2021-02-15 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
CN113396158A
(zh)
|
2018-11-26 |
2021-09-14 |
诺华股份有限公司 |
Lpl-gpihbp1融合多肽
|
WO2020198731A2
(en)
|
2019-03-28 |
2020-10-01 |
Danisco Us Inc |
Engineered antibodies
|
MX2021014164A
(es)
|
2019-05-21 |
2022-01-04 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas.
|
US20230071196A1
(en)
|
2019-05-21 |
2023-03-09 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
WO2020242989A1
(en)
|
2019-05-24 |
2020-12-03 |
Sanofi |
Methods for treating systemic sclerosis
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
IL302569A
(en)
|
2020-11-06 |
2023-07-01 |
Novartis Ag |
CD19 binding molecules and their uses
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
US11773160B1
(en)
|
2022-08-05 |
2023-10-03 |
Anaveon AG |
Immune-stimulating IL-2 fusion proteins
|